Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS

Untitled work

Hao (2015) · doi:10.1002/14651858 · Cited by 11,321 · see citing works

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · see citing works

Central nervous system control of food intake

Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · see citing works

Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans

Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326 · see citing works

Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010.

Flegal, K., Carroll, M., Kit, B., & Ogden, C. (2012) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2012.39 · Cited by 5,523 · see citing works

IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030

Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. E. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 3,994 · see citing works

The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · see citing works

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works

Role of Brain Insulin Receptor in Control of Body Weight and Reproduction

Brüning, J. C., Gautam, D., Burks, D. J., Gillette, J., Schubert, M., Orban, P. C., Klein, R., Krone, W., Müller-Wieland, D., & Kahn, C. R. (2000) · Science · doi:10.1126/science.289.5487.2122 · Cited by 2,235 · see citing works

The biology of incretin hormones

Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · see citing works

A role for glucagon-like peptide-1 in the central regulation of feeding

Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · see citing works

Glucagon-like peptide-1 7–36: a physiological incretin in man

Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · see citing works

Impact of Overweight on the Risk of Developing Common Chronic Diseases During a 10-Year Period

Field, A. E., Coakley, E. H., Must, A., Spadano, J. L., Laird, N., Dietz, W. H., Rimm, E., & Colditz, G. A. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.13.1581 · Cited by 1,694 · see citing works

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · see citing works

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · see citing works

Long-term weight-loss maintenance: a meta-analysis of US studies

Anderson, J. W., Konz, E. C., Frederich, R. C., & Wood, C. L. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/74.5.579 · Cited by 1,351 · see citing works

Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · see citing works

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · see citing works

Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study

Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · see citing works

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · see citing works

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · see citing works

Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons

Woods, S. C., Lotter, E. C., McKay, L. D., & Porte, D. (1979) · Nature · doi:10.1038/282503a0 · Cited by 1,114 · see citing works

How can drug addiction help us understand obesity?

Volkow, N. D., & Wise, R. A. (2005) · Nature Neuroscience · doi:10.1038/nn1452 · Cited by 1,089 · see citing works

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · see citing works

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · see citing works

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · see citing works

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.

Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · see citing works

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.

Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882 · see citing works

Review of article: Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010 by Katherine M. Flegal, PhD; Margaret D. Carroll, MSPH; Brian K. Kit, MD; Cynthia L. Ogden, PhD (JAMA 2012;307:491-7)

Fitzgerald, K. R. (2013) · Journal of Vascular Nursing · doi:10.1016/j.jvn.2013.06.004 · Cited by 875 · see citing works

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · see citing works

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · see citing works

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835 · see citing works

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans

Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R. A., & Schmiegel, W. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 822 · see citing works

Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)

Marre, M., Shaw, J. E., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M. D., Thi, T. D. L., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 814 · see citing works

Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes: A Randomized Trial

Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795 · see citing works

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · see citing works

Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects.

Polonsky, K. S., Given, B. D., & Van Cauter, E. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113339 · Cited by 763 · see citing works

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · see citing works

Reward mechanisms in obesity: new insights and future directions

Kenny, P. J. (2011) · Neuron · doi:10.1016/j.neuron.2011.02.016 · Cited by 748 · see citing works

Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration

Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 705 · see citing works

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698 · see citing works

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem

Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663 · see citing works

Selective deletion of leptin receptor in neurons leads to obesity

Cohen, P., Zhao, C., Cai, X., Montez, J. M., Rohani, S., Feinstein, P. G., Mombaerts, P., & Friedman, J. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13914 · Cited by 657 · see citing works

Homeostatic and hedonic signals interact in the regulation of food intake

Lutter, M., & Nestler, E. J. (2009) · The Journal of Nutrition · doi:10.3945/jn.108.097618 · Cited by 614 · see citing works

A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7–36) Amide on Ad Libitum Energy Intake in Humans

Verdich, C., Flint, A., Gutzwiller, J., Näslund, E. B., Beglinger, C., Hellström, P. M., Long, S. J., Morgan, L., Holst, J. J., & Astrup, A. V. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7877 · Cited by 600 · see citing works

The inhibitory effects of peripheral administration of peptide YY3–36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal–brainstem–hypothalamic pathway

Abbott, C. R., Monteiro, M. P., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Ghatei, M. A., & Bloom, S. R. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.011 · Cited by 597 · see citing works

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)

Holz, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 594 · see citing works

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · see citing works

Selective deletion of leptin receptor in neurons leads to obesity

Cohen, P., Zhao, C., Cai, X., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200113914 · Cited by 554 · see citing works

Diet-Induced Obesity Causes Severe but Reversible Leptin Resistance in Arcuate Melanocortin Neurons

Enriori, P. J., Evans, A. E., Sinnayah, P., Jobst, E. E., Tonelli-Lemos, L., Billes, S. K., Glavas, M. M., Grayson, B. E., Perello, M., Nillni, E. A., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.02.004 · Cited by 552 · see citing works

Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2

Gutzwiller, J., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521 · see citing works

Similarity Between Obesity and Drug Addiction as Assessed by Neurofunctional Imaging: A Concept Review

Wang, G.-J., Volkow, N. D., Thanos, P. K., & Fowler, J. S. (2004) · Journal of Addictive Diseases · doi:10.1300/j069v23n03_04 · Cited by 502 · see citing works

Metabolic and hedonic drives in the neural control of appetite: who is the boss?

Berthoud, H. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.09.004 · Cited by 501 · see citing works

Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier

Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480 · see citing works

Peripheral Signals Conveying Metabolic Information to the Brain: Short-Term and Long-Term Regulation of Food Intake and Energy Homeostasis

Havel, P. J. (2001) · Experimental Biology and Medicine · doi:10.1177/153537020122601102 · Cited by 476 · see citing works

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

Nielsen, L. L., Young, A. A., & Parkes, D. G. (2003) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 455 · see citing works

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

Young, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440 · see citing works

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434 · see citing works

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

Nauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R. G., & TRAUTMANN, M. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 430 · see citing works

The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors

Dickson, S. L., Shirazi, R. H., Hansson, C., Bergquist, F., Nissbrandt, H., & Skibicka, K. P. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6326-11.2012 · Cited by 414 · see citing works

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans

Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · see citing works

One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients

Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388 · cited 1× · see citing works

A Recombinant Human Glucagon-Like Peptide (GLP)-1–Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor–Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis

Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2492 · Cited by 388 · see citing works

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · see citing works

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure

Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372 · see citing works

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369 · see citing works

The Gut Hormones PYY3-36 and GLP-17-36 amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans

Silva, A. D., Salem, V., Long, C. J., Makwana, A., Newbould, R. D., Rabiner, E. A., Ghatei, M. A., Bloom, S. R., Matthews, P. M., Beaver, J. D., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.09.010 · Cited by 351 · see citing works

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

Moretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350 · see citing works

Review article: the role of gastric motility in the control of food intake

Janssen, P., Berghe, P. V., Verschueren, S., Lehmann, A., Depoortere, I., & Tack, J. F. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04609.x · Cited by 347 · see citing works

A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7-36) Amide on Ad Libitum Energy Intake in Humans

Verdich, C. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4382 · Cited by 340 · see citing works

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 339 · see citing works

Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats

Vahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., et al. (2007) · Endocrinology · doi:10.1210/en.2006-0153 · Cited by 318 · see citing works

Arcuate Glucagon-Like Peptide 1 Receptors Regulate Glucose Homeostasis but Not Food Intake

Sandoval, D. A., Bagnol, D., Woods, S. C., D’Alessio, D. A., & Seeley, R. J. (2008) · Diabetes · doi:10.2337/db07-1824 · Cited by 316 · see citing works

Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312 · see citing works

Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men

Näslund, E. B., Gutniak, M., Skogar, S., Rössner, S., & Hellström, P. M. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.3.525 · Cited by 307 · see citing works

The expression of GLP‐1 receptor mRNA and protein allows the effect of GLP‐1 on glucose metabolism in the human hypothalamus and brainstem

Álvarez, E., Martínez, M. D., Roncero, I., Chowen, J. A., Cuartero, B. G., Gispert, J. D., Sanz, C., Vázquez, P., Maldonado, A., Cáceres, J. D., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02914.x · Cited by 307 · see citing works

Peripheral Exendin-4 and Peptide YY3–36 Synergistically Reduce Food Intake through Different Mechanisms in Mice

Talsania, T., Anini, Y., Siu, S., Drucker, D. J., & Brubaker, P. L. (2005) · Endocrinology · doi:10.1210/en.2005-0473 · Cited by 306 · see citing works

Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats

Szayna, M., Doyle, M. E., Betkey, J. A., Holloway, H. W., Spencer, R. G. S., Greig, N. H., & Egan, J. M. (2000) · Endocrinology · doi:10.1210/endo.141.6.7490 · Cited by 303 · see citing works

Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety

Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2009) · Endocrinology · doi:10.1210/en.2008-1045 · Cited by 300 · see citing works

Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin

Benedict, C., Kern, W., Schultes, B., Born, J., & Hallschmid, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2606 · Cited by 296 · cited 1× · see citing works

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

Holst, J. J., & Deacon, C. F. (2005) · Diabetologia · doi:10.1007/s00125-005-1705-7 · Cited by 287 · see citing works

Reduced central leptin sensitivity in rats with diet-induced obesity

Levin, B. E., & Dunn-Meynell, A. A. (2002) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00245.2002 · Cited by 264 · see citing works

Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms

Rüttimann, E. B., Arnold, M., Hillebrand, J. J., Geary, N., & Langhans, W. (2008) · Endocrinology · doi:10.1210/en.2008-1221 · Cited by 258 · see citing works

Glucagon-Like Peptide 1 Receptors in Nucleus Accumbens Affect Food Intake

Dossat, A. M., Lilly, N., Kay, K. E., & Williams, D. L. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3262-11.2011 · Cited by 256 · see citing works

Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia)

Seino, Y., Min, K. W., Niemoeller, E., Takami, A., & on behalf of the EFC10887 GETGOAL‐L Asia Study Investigators (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01618.x · Cited by 255 · see citing works

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine

Riddle, M. C., Forst, T. M., Aronson, R., Sauque‐Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 251 · see citing works

Rapid development of tolerance to the behavioural actions of cholecystokinin

Crawley, J. N., & Beinfeld, M. C. (1983) · Nature · doi:10.1038/302703a0 · Cited by 243 · see citing works

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240 · see citing works

Direct Control of Brown Adipose Tissue Thermogenesis by Central Nervous System Glucagon-Like Peptide-1 Receptor Signaling

Lockie, S. H., Heppner, K. M., Chaudhary, N., Chabenne, J. R., Morgan, D. A., Veyrat‐Durebex, C., Ananthakrishnan, G., Rohner‐Jeanrenaud, F., Drucker, D. J., DiMarchi, R. D., et al. (2012) · Diabetes · doi:10.2337/db11-1556 · Cited by 238 · see citing works

The Effect of Liraglutide, a Long-Acting Glucagon-Like Peptide 1 Derivative, on Glycemic Control, Body Composition, and 24-h Energy Expenditure in Patients With Type 2 Diabetes

Harder, H., Nielsen, L., Thi, T. D. T., & Astrup, A. V. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1915 · Cited by 232 · see citing works

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

Rosenstock, J., Klaff, L. J., Schwartz, S., Northrup, J., Holcombe, J. H., Wilhelm, K., & Trautmann, M. (2010) · Diabetes Care · doi:10.2337/dc09-1203 · Cited by 229 · see citing works

Effects of Intravenous Glucagon-Like Peptide-1 on Gastric Emptying and Intragastric Distribution in Healthy Subjects: Relationships with Postprandial Glycemic and Insulinemic Responses

Little, T. J., Pilichiewicz, A. N., Russo, A., Phillips, L. K., Jones, K. L., Nauck, M. A., Wishart, J. M., Horowitz, M., & Feinle‐Bisset, C. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2220 · Cited by 214 · see citing works

Liraglutide, a once‐daily human glucagon‐like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

Garber, A. J., Henry, R. R., Ratner, R. E., Hale, P. M., Chang, C., & Bode, B. W. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01356.x · Cited by 195 · see citing works

Untitled work

Anthony (2006) · doi:10.2337/db06-0376 · Cited by 195 · see citing works

The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty

Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Wettergren, A., Svendsen, L. B., Meisner, S., Hovendal, C. P., Vilsbøll, T., Knop, F. K., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00035.2013 · Cited by 183 · see citing works

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes

Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179 · see citing works

Liraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight

Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang‐Christensen, M., & Knudsen, L. B. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01557.x · Cited by 175 · see citing works

Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus.

Shughrue, P. J., Lane, M. V., & Merchenthaler, I. J. (1996) · Endocrinology · doi:10.1210/endo.137.11.8895391 · Cited by 175 · see citing works

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

Ulrich, W., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 173 · see citing works

Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

Bunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care · doi:10.2337/dc09-2361 · Cited by 161 · see citing works

Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats

de Fonseca, F. R., Navarro, M. A., Álvarez, E., Roncero, I., Chowen, J. A., Maestre, O., de Heras, R. G., Muñoz, R. M., Eng, J., & Blázquez, E. (2000) · Metabolism · doi:10.1053/meta.2000.6251 · Cited by 157 · see citing works

Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans

Pannacciulli, N., Le, D. S. N. T., Salbe, A. D., Chen, K., Reiman, E. M., Tataranni, P. A., & Krakoff, J. A. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.12.035 · Cited by 154 · see citing works

Neuronal control of energy homeostasis

Gao, Q., & Horváth, T. L. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.11.063 · Cited by 153 · see citing works

Glucagon-like peptide 1-(7–36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats

Schick, R., Zimmermann, J., Walde, T. V., & SCHUSDZIARRA, V. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00479.2002 · Cited by 152 · see citing works

The effect of glucagon-like peptide 1 on cardiovascular risk

Sivertsen, J., Rosenmeier, J. B., Holst, J. J., & Vilsbøll, T. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.211 · Cited by 147 · see citing works

Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)

Bolli, G. B., Munteanu, M., Dotsenko, S., Niemoeller, E., Boka, G., Wu, Y., & Hanefeld, M. (2014) · Diabetic Medicine · doi:10.1111/dme.12328 · Cited by 144 · see citing works

Exenatide compared with long‐acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long‐Acting insulin (HEELA) study

Davies, M. J., Donnelly, R., Barnett, A. H., Jones, S., Nicolay, C., & Kilcoyne, A. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01154.x · Cited by 144 · see citing works

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone ( GetGoal ‐P)

Pinget, M., Goldenberg, R., Niemoeller, E., Muehlen-Bartmer, I., Guo, H., & Aronson, R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12121 · Cited by 140 · see citing works

Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function

Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138 · see citing works

Effects of glucagon-like peptide-1(7–36)amide on motility and sensation of the proximal stomach in humans

Schirra, J., Wank, U., Arnold, R., Göke, B., & Katschinski, M. (2002) · Gut · doi:10.1136/gut.50.3.341 · Cited by 130 · see citing works

Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats

Chelikani, P. K., Haver, A. C., & Reidelberger, R. D. (2005) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00870.2004 · Cited by 128 · see citing works

Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4.

Raufman, J., Singh, L., Singh, G., & Eng, J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36628-1 · Cited by 122 · see citing works

The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans

Flint, A., Raben, A., Jf, R., Holst, J. J., & Astrup, A. V. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801126 · Cited by 120 · see citing works

Stimulation of Cholecystokinin-A Receptors With GI181771X does not Cause Weight Loss in Overweight or Obese Patients

Jordan, J., Greenway, F., Leiter, L., Li, Z., Jacobson, P., Murphy, K. E., Hill, J. O., Kler, L., & Aftring, R. P. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100272 · Cited by 120 · see citing works

Glucagon‐like peptide‐1 in the rat brain: Distribution of expression and functional implication

Gu, G., Roland, B. L., Tomaselli, K. J., Dolman, C. S., Lowe, C., & Heilig, J. S. (2012) · The Journal of Comparative Neurology · doi:10.1002/cne.23282 · Cited by 119 · see citing works

GLP‐1 based therapies: differential effects on fasting and postprandial glucose

Fineman, M. S., Cirincione, B. B., Maggs, D. G., & Diamant, M. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01560.x · Cited by 114 · see citing works

The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size

Scott, K. A., & Moran, T. H. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00323.2007 · Cited by 113 · see citing works

Brain Glucagon-Like Peptide 1 Signaling Controls the Onset of High-Fat Diet-Induced Insulin Resistance and Reduces Energy Expenditure

Knauf, C., Cani, P. D., Ait-Belgnaoui, A., Bénani, A., Dray, C., Cabou, C., Colom, A., Uldry, M., Rastrelli, S., Sabatier, E., et al. (2008) · Endocrinology · doi:10.1210/en.2008-0180 · Cited by 99 · see citing works

Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice

Tweedie, D., Rachmany, L., Rubovitch, V., Lehrmann, E., Zhang, Y., Becker, K. G., Perez, E., Miller, J. P., Hoffer, B. J., Greig, N. H., et al. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.10.001 · Cited by 90 · see citing works

Exenatide-Induced Reduction in Energy Intake Is Associated With Increase in Hypothalamic Connectivity

Schlögl, H., Kabisch, S., Horstmann, A., Lohmann, G., Müller, K., Lepsien, J., Busse, F. P., Kratzsch, J., Pleger, B., Villringer, A., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1925 · Cited by 89 · see citing works

Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes

Gallwitz, B., Böhmer, M., Segiet, T., Mölle, A., Milek, K., Becker, B., Helsberg, K., Petto, H., Peters, N., & Bachmann, O. P. (2011) · Diabetes Care · doi:10.2337/dc10-1900 · Cited by 88 · see citing works

Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging

Chaudhri, O. B., Parkinson, J. R. C., Kuo, Y., Druce, M. R., Herlihy, A. H., Bell, J. D., Dhillo, W. S., Stanley, S. A., Ghatei, M. A., & Bloom, S. R. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.09.033 · Cited by 87 · see citing works

The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1

Hayes, M. R., Kanoski, S. E., De Jonghe, B. C., Leichner, T. M., Alhadeff, A. L., Fortin, S. M., Arnold, M., Langhans, W., & Grill, H. J. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00356.2011 · Cited by 86 · see citing works

Leptin and Amylin Act in an Additive Manner to Activate Overlapping Signaling Pathways in Peripheral Tissues

Moon, H., Chamberland, J. P., Diakopoulos, K. N., Fiorenza, C. G., Ziemke, F., Schneider, B. E., & Mantzoros, C. S. (2010) · Diabetes Care · doi:10.2337/dc10-0518 · Cited by 85 · see citing works

Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system

Osaka, T., Endo, M., Yamakawa, M., & Inoue, S. (2005) · Peptides · doi:10.1016/j.peptides.2005.02.016 · Cited by 84 · see citing works

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea

Bergenstal, R. M., Lewin, A. J., Bailey, T. S., Chang, D., Gylvin, T., Roberts, V. L., & for the NovoLog Mix-vs.-Exenatide Study Group (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802597951 · Cited by 82 · see citing works

Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes

Barnett, A. H. (2011) · Core evidence · doi:10.2147/ce.s15525 · Cited by 80 · see citing works

Neural mechanisms underlying obesity and drug addiction

Trinko, R., Sears, R. M., Guarnieri, D. J., & Dileone, R. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.01.001 · Cited by 75 · see citing works

Glucagon-like peptide-1 and glucagon-like peptide-2

Baggio, L. L., & Drucker, D. J. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.001 · Cited by 73 · see citing works

Additive Glucose-Lowering Effects of Glucagon-Like Peptide-1 and Metformin in Type 2 Diabetes

Zander, M., Taskiran, M., Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.720 · Cited by 60 · see citing works

Differential Effects of Intracerebroventricular Glucagon-Like Peptide-1 on Feeding and Energy Expenditure Regulation

Hwa, J. J., Ghibaudi, L., Williams, P., Witten, M. B., Tedesco, R., & Strader, C. D. (1998) · Peptides · doi:10.1016/s0196-9781(98)00033-3 · Cited by 59 · see citing works

GSK1614343, a Novel Ghrelin Receptor Antagonist, Produces an Unexpected Increase of Food Intake and Body Weight in Rodents and Dogs

Costantini, V. J. A., Vicentini, E., Sabbatini, F. M., Valerio, E., Lepore, S., Tessari, M., Sartori, M., Michielin, F., Melotto, S., Pich, E. M., et al. (2011) · Neuroendocrinology · doi:10.1159/000328968 · Cited by 55 · see citing works

Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus

Shughrue, P. J. (1996) · Endocrinology · doi:10.1210/en.137.11.5159 · Cited by 49 · see citing works

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years

Remillard, C. V., MacConell, Li, Pencek, Maggs, & Porter (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s35801 · Cited by 48 · see citing works

Alterations in energy balance following exenatide administration

Bradley, D. P., Kulstad, R., Racine, N. M., Shenker, Y., Meredith, M., & Schoeller, D. A. (2012) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h2012-068 · Cited by 47 · see citing works

Changes in Differential Functional Magnetic Resonance Signals in the Rodent Brain Elicited by Mixed-Nutrient or Protein-Enriched Meals

Min, D., Tuor, U. I., Koopmans, H. S., & Chelikani, P. K. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.034 · Cited by 45 · see citing works

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus

Petersen, B., & Christensen, M. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s45379 · Cited by 42 · see citing works

Intraportal administration of DPP‐IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats

Fujiwara, K., Gotoh, K., Chiba, S., Masaki, T., Katsuragi, I., Kakuma, T., & Yoshimatsu, H. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07563.x · Cited by 41 · see citing works

BDNF-TrkB signaling interacts with the GABAergic system to inhibit rhythmic swallowing in the rat

Bariohay, B., Tardivel, C., Pio, J., Jean, A., & Félix, B. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90407.2008 · Cited by 33 · see citing works

Non‐glycaemic effects mediated via GLP‐1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide

Vilsbøll, T., & Garber, A. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01579.x · Cited by 30 · see citing works

Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide

van Genugten, R. E., van Raalte, D. H., & Diamant, M. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(09)70006-3 · Cited by 26 · see citing works

Leptin therapy in type 2 diabetes

Cummings, B. P. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12048 · Cited by 23 · see citing works

Nutrient control of hunger by extrinsic gastrointestinal neurons

Mithieux, G. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.04.005 · Cited by 19 · see citing works

A tasty morsel: the role of the dorsal vagal complex in the regulation of food intake and swallowing. Focus on “BDNF/TrkB signaling interacts with GABAergic system to inhibit rhythmic swallowing in the rat,” by Bariohay et al.

Bailey, E. F. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90701.2008 · Cited by 14 · see citing works

Untitled work

Barbero (2014) · doi:10.1016/j · Cited by 1 · see citing works

Untitled work

Merchenthaler (1999) · doi:10.1002/(sici)1096-9861(19990111)403:2

The Discovery and Development of Liraglutide and Semaglutide

Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970 · see citing works

GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans

van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427 · see citing works

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407 · see citing works

Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus

Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358 · see citing works

Safety of Semaglutide

Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332 · see citing works

Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials

Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280 · see citing works

Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation

Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H., Peters, T. M., & Eisenberg, M. J. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.01.021 · Cited by 241 · see citing works

GLP-1 acts on habenular avoidance circuits to control nicotine intake

Tuesta, L. M., Chen, Z., Duncan, A., Fowler, C. D., Ishikawa, M., Lee, B. R., Liu, X.-A., Lu, Q., Cameron, M., Hayes, M. R., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4540 · Cited by 200 · see citing works

Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease

McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.015 · Cited by 170 · see citing works

Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons

Adams, J. M., Pei, H., Sandoval, D. A., Seeley, R. J., Chang, R. B., Liberles, S. D., & Olson, D. P. (2018) · Diabetes · doi:10.2337/db17-1385 · Cited by 159 · see citing works

Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program

Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158 · see citing works

GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1

Xu, F., Lin, B., Zheng, X., Chen, Z., Cao, H., Xu, H., Liang, H., & Weng, J. (2016) · Diabetologia · doi:10.1007/s00125-016-3896-5 · Cited by 157 · see citing works

Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans

van Bloemendaal, L., Veltman, D. J., ten Kulve, J. S., Groot, P. F. C., Ruhé, H. G., Barkhof, F., Sloan, J. H., Diamant, M., & Ijzerman, R. G. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12506 · Cited by 151 · see citing works

Centrally Acting Agents for Obesity: Past, Present, and Future

Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151 · see citing works

The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome

Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084334 · Cited by 148 · see citing works

Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes

Heuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106 · see citing works

G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus

Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014373 · Cited by 108 · see citing works

Dapagliflozin once‐daily and exenatide once‐weekly dual therapy: A 24‐week randomized, placebo‐controlled, phase <scp>II</scp> study examining effects on body weight and prediabetes in obese adults without diabetes

Lundkvist, P., Sjöström, C. D., Amini, S., Pereira, M. J., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12779 · Cited by 108 · see citing works

Emerging pharmacotherapies for obesity: A systematic review

Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102 · see citing works

Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study

Jensterle, M., Pirš, B., Goričar, K., Dolžan, V., & Janež, A. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1868-1 · Cited by 86 · see citing works

Gastrointestinal actions of glucagon‐like peptide‐1‐based therapies: glycaemic control beyond the pancreas

Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74 · see citing works

Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: <scp>S</scp> ustained reductions in body weight, glycaemia and blood pressure over 1 year

Lundkvist, P., Pereira, M. J., Katsogiannos, P., Sjöström, C. D., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12954 · Cited by 72 · see citing works

The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls

Kahal, H., Aburima, A., Ungvari, T., Rigby, A. S., Coady, A. M., Vince, R. V., Ajjan, R. A., Kilpatrick, E. S., Naseem, K. M., & Atkin, S. L. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0005-6 · Cited by 74 · see citing works

Weight loss effect of glucagon‐like peptide‐1 mimetics on obese/overweight adults without diabetes: A systematic review and meta‐analysis of randomized controlled trials胰高血糖素样肽‐1类似物对非糖尿病肥胖/超重成人的减重作用：一篇对随机对照试验进行的系统评价及meta分析

Zhang, F., Tong, Y., Su, N., Li, Y., Tang, L., Huang, L., & Tong, N. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12198 · Cited by 59 · see citing works

Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss

Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58 · see citing works

Twelve weeks of exenatide treatment increases [18F] fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males

Janssen, L. G. M., Nahon, K. J., Bracké, K. F. M., van den Broek, D., Smit, R., Sardjoe Mishre, A. S. D., Koorneef, L. L., Martinez-Tellez, B., Burakiewicz, J., Kan, H. E., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154167 · Cited by 54 · see citing works

Gut Microbiome and Modulation of <scp>CNS</scp> Function

Osadchiy, V., Martin, C. R., & Mayer, E. A. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180031 · Cited by 53 · see citing works

Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study

Pratley, R. E., Kang, J., Trautmann, M. E., Hompesch, M., Han, O., Stewart, J., Sorli, C. H., Jacob, S., & Yoon, K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13824 · Cited by 49 · see citing works

<scp>Glucagon‐like peptide</scp> ‐1 <scp>receptor agonist</scp> ‐based agents and weight loss composition: Filling the gaps

Dubin, R. L., Heymsfield, S. B., Ravussin, E., & Greenway, F. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15913 · Cited by 47 · see citing works

Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis

Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Endocrine · doi:10.1007/s12020-014-0373-0 · Cited by 44 · see citing works

Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison

le Roux, C. W., Hankosky, E. R., Wang, D., Malik, R., Yu, M., Hickey, A., Kan, H., Bunck, M. C., Stefanski, A., Garcia‐Perez, L., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15148 · Cited by 36 · see citing works

Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double‐blind, placebo‐controlled phase <scp>3a</scp> clinical trial

Shuai, Y., Yang, G., Zhang, Q., Li, W., Luo, Y., Ma, J., Chen, D., Yang, J., Wang, X., Hu, J., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14198 · Cited by 35 · see citing works

Efficacy and tolerability of the subcutaneous semaglutide for type 2 diabetes patients: an updated systematic review and meta-analysis

Hu, S., Su, X., & Fan, G. (2023) · Diabetology &amp; Metabolic Syndrome · doi:10.1186/s13098-023-01195-7 · Cited by 28 · see citing works

Legend of Weight Loss: A Crosstalk Between the Bariatric Surgery and the Brain

Lin, Z., & Qu, S. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04474-8 · Cited by 28 · see citing works

Endogenous GLP‐1 alters postprandial functional connectivity between homeostatic and reward‐related brain regions involved in regulation of appetite in healthy lean males: A pilotstudy

Meyer‐Gerspach, A. C., Ly, H. G., Borgwardt, S., Dupont, P., Beglinger, C., Van Oudenhove, L., & Wölnerhanssen, B. K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13369 · Cited by 25 · see citing works

Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors

Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24 · see citing works

Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients

Gao, L., Huang, H., Zhang, L., Zhang, N., Fu, Y., Zhu, D., Bi, Y., & Feng, W. (2022) · Experimental and Clinical Endocrinology &amp; Diabetes · doi:10.1055/a-1608-0345 · Cited by 24 · see citing works

Weight loss and side-effects of liraglutide and lixisenatide in obesity and type 2 diabetes mellitus

Lee, J., Kim, R., Kim, M.-H., Lee, S.-H., Cho, J.-H., Lee, J. M., Jang, S.-A., & Kim, H.-S. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.07.006 · Cited by 20 · see citing works

Glucagon-like Peptide-1 Receptor in the Human Hypothalamus Is Associated with Body Mass Index and Colocalizes with the Anorexigenic Neuropeptide Nucleobindin-2/Nesfatin-1

Psilopanagioti, A., Nikou, S., Logotheti, S., Arbi, M., Chartoumpekis, D. V., & Papadaki, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314899 · Cited by 22 · see citing works

Potential contributors to variation in weight‐loss response to liraglutide

Webster, C. M., Mittal, N., Dhurandhar, E. J., & Dhurandhar, N. V. (2023) · Obesity Reviews · doi:10.1111/obr.13568 · Cited by 19 · see citing works

One month weight loss predicts the efficacy of Liraglutide in obese patients: data from a single center

Maccora, C., Ciuoli, C., Goracci, A., Benenati, N., Formichi, C., Pilli, T., Verdino, V., Mnutr, O. N., Bufano, A., Tirone, A., et al. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0169 · Cited by 19 · see citing works

Centrally located GLP-1 receptors modulate gastric slow waves and cardiovascular function in ferrets consistent with the induction of nausea

Lu, Z., Yeung, C.-K., Lin, G., Yew, D. T. W., Andrews, P. L. R., & Rudd, J. A. (2017) · Neuropeptides · doi:10.1016/j.npep.2017.04.006 · Cited by 13 · see citing works

Incretin hormones and the satiation signal

Holst, J. J. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.208 · Cited by 187 · see citing works

Treatment of Obese Diabetics

Svacina, S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_32 · Cited by 8 · see citing works

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes

Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394 · see citing works

Incretin dysfunction and hyperglycemia in cystic fibrosis: Role of acyl-ghrelin

Sun, X., Yi, Y., Liang, B., Yu, Y., He, N., Ode, K. L., Uç, A., Wang, K., Gibson-Corley, K. N., Engelhardt, J. F., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.01.010 · Cited by 7 · see citing works

Ghrelin Does Not Directly Stimulate Secretion of Glucagon-like Peptide-1

Jepsen, S. L., Vestergaard, E. T., Larraufie, P., Gribble, F. M., Reimann, F. M., Jørgensen, J. O. L., Holst, J. J., & Kuhre, R. E. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz046 · Cited by 11 · see citing works